Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Aug 1;23(8):e386-e391.
doi: 10.1097/PCC.0000000000002969. Epub 2022 Jun 10.

Polymyxin B Hemoperfusion in Pediatric Septic Shock: Single-Center Observational Case Series

Affiliations
Observational Study

Polymyxin B Hemoperfusion in Pediatric Septic Shock: Single-Center Observational Case Series

Patcharin Saetang et al. Pediatr Crit Care Med. .

Abstract

Objectives: To evaluate the use of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) as adjunctive therapy during pediatric patients with septic shock.

Design: Prospective observational study.

Setting: Nine-bed PICUs at university referral hospital.

Patients: Children (30 d to 15 yr) with septic shock and Pediatric Logistic Organ Dysfunction (PELOD)-2 score greater than or equal to 10 or Pediatric Risk of Mortality (PRISM) 3 score greater than or equal to 15, who were also receiving at least one inotrope.

Intervention: Patients received 2-4 hour treatment with PMX-DHP 20R column on 2 consecutive days.

Measurements and main results: We enrolled six children aged 21-167 months old (median, 99-mo old), with a body weight of 10-50 kg (median, 28 kg). All six patients had both PELOD-2 greater than or equal to 10 and PRISM-3 greater than or equal to 15, required invasive mechanical ventilation, and received standard treatment for septic shock before enrollment. We observed significant improvement in PELOD-2 score from baseline to 72 hours after the start of PMX-DHP (mean [95% CI] from 14.3 [12.2-16.5] to 6.0 [0.3-11.7]; p = 0.006). The vasoactive inotropic score (VIS) and lactate concentration also significantly decreased from baseline to 72 hours (VIS, 60 mmol/L [25-95 mmol/L] to 4.0 mmol/L [44.1-12 mmol/L]; p = 0.003; lactate, 2.4 mmol/L [1.0-3.8 mmol/L] to 1.0 mmol/L [0.5-1.5 mmol/L]; p = 0.01). Five of six patients survived. There was no device-related adverse event in these patients.

Conclusions: In this case series of treatment with PMX-DHP as adjunctive therapy in children with refractory septic shock and high baseline severity, we have shown that patient recruitment is feasible. We have also found that clinical hemodynamic and severity of illness scores at 72 hours may be potential end points for testing in future randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

Drs. Saetang and Samransamruajkit received funding from Ratchadaphiseksomphot Endowment Fund from Faculty of Medicine, Chulalongkorn University. Toray industries supported PMX 20R cartridges. Nikkiso Medical and Infomed supported blood lines. All companies were not related to study protocol, data collection, statistical analysis, and discussion. Drs. Saetang and Singjam received support for article research from the Ratchadaphiseksomphot Endowment Fund from Faculty of Medicine, Chulalongkorn University. Dr. Singjam disclosed work for hire. Dr. Deekajorndech has disclosed that he does not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Changes in Pediatric Logistic Organ Dysfunction (PELOD)-2 scores (A) and vascular inotropic score (VIS) (B) from baseline (BL) until 72 hr. Case 5 is not shown in this figure because of death. Friedman test was used to compare the values.

References

    1. Vincent JL, De Backer D: Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care 2005; 9(Suppl 4):S9–S12 - PMC - PubMed
    1. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420:885–891 - PubMed
    1. Rimmelé T, Kellum JA: Clinical review: Blood purification for sepsis. Crit Care 2011; 15:205. - PMC - PubMed
    1. Davies B, Cohen J: Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011; 11:65–71 - PubMed
    1. Gulla KM, Sachdev A, Gupta D, et al. : Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction - a pilot study on timing of initiation. Indian J Crit Care Med 2015; 19:613–617 - PMC - PubMed

Publication types